Fulcrum Therapeutics, Inc. · NASDAQ:FULC
Fulcrum Therapeutics — AAN 2022
22 slides from Fulcrum Therapeutics's conference presentation, April 2022
Slide 1: ReDUX4: Phase 2 Study of Losmapimod in FSHD
A phase 2, randomized, double-blind, placebo-controlled, 48-Week study of the efficacy and safety of losmapimod in subjects with FSHD: ReDUX4 Christopher Morabito, MD, Chief Medical Officer, Fulcrum Therapeutics FULCRUM THERAPEUTICS 1
Slide 2: Disclosure Statement
Disclosure Statement ▪ Dr. Christopher Morabito is a full-time employee of Fulcrum Therapeutics. FULCRUM THERAPEUTICS 2
Slide 3: No Treatment Options for People Living With FSHD That Address Disease Progression
Currently, There Are No Treatment Options for People Living With FSHD That Address Disease Progression FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY (FSHD) is caused by the aberrant expression of DUX4 in skeletal muscle STOCHASTIC DUX4 EXPRESSION contributes to disease heterogeneity, asymmetry, and variabi
Slide 4: Losmapimod, a selective p38 MAPK inhibitor, blocks DUX4-driven gene expression
Losmapimod, a selective p38 MAPK inhibitor, blocks DUX4- driven gene expression FulcrumSeekTM identified losmapimod as drug candidate to treat root cause of FSHD ▪ Highly selective p38α/β MAPK inhibitor ▪ Reduced DUX4 expression in preclinical studies ▪ Aberrant expression DUX4 gene is known root ca
Slide 5: ReDUX4 Trial Design
ReDUX4 Trial Design* Baseline Assessment 7-Day Safety & Randomization Follow-Up 48-Week Placebo-Controlled Treatment Period 28-day Placebo tablet twice per day (N=40) Open Label Screening Extension (OLE) Period Losmapimod tablet 15 mg twice per day (N=40) Study (N=76) MRI Visit 1 Visit 2 Visit 3 Vis
Slide 6: ReDUX4 Study Participant Randomization Was Well Balanced
ReDUX4 Study Participant Randomization Was Well Balanced Placebo Losmapimod BID (N=40) 15 mg BID (N=40) Completed 38 (95%) 39 (97.5%) Discontinued* 2 (5.0%) 1 (2.5%) DEMOGRAPHICS N 40 40 Age (years) Mean (SD) 45.7 (+/- 12.69) 45.7 (+/- 12.44) White 39 (97.5) 31 (77.5) Asian 0 5 (12.5) Race n (%) Oth
Slide 7: Expected Pharmacokinetic and Target Engagement in Blood and Muscle
Losmapimod Exhibited Expected Pharmacokinetic and Target Engagement in Blood and Muscle as Observed in Previous FSHD Studies ▪ Blood concentrations consistent with previous studies ▪ Muscle exposures of losmapimod were within expected range 30 ng/mL ▪ Levels of pHSP27/tHSP27 in blood after sorbitol
Slide 8: Primary Endpoint: Reduction of DUX4-Driven Gene Expression in Muscle Biopsies
Primary Endpoint: Reduction of DUX4-Driven Gene Expression in Muscle Biopsies Changes in either group were not observed in the treatment period*, and the primary endpoint was not met ▪ Subgroup analysis by quartile of DUX4-driven gene expression showed no differences ▪ DUX4-driven gene expression wa
Slide 9: Significantly Less Muscle Fat Infiltration vs Placebo in Intermediate Muscles
Losmapimod Treated Participants Showed Significantly Less Muscle Fat Infiltration (MFI) vs Placebo in Intermediate Muscles* Muscle Fat Infiltration (MFI) Muscle Fat Fraction (MFF) Lean Muscle Volume (LMV) Intermediate Muscles Intermediate Muscles Intermediate Muscles 0 Worsening ✱ p=0.38 Change from
Slide 10: Normal-Appearing Muscles Appear Preserved With Losmapimod vs Placebo
Normal-Appearing Muscles Appear Preserved With Losmapimod vs Placebo* Muscle Fat Infiltration (MFI) Muscle Fat Fraction (MFF) Lean Muscle Volume (LMV) Normal-Appearing Muscles Normal-Appearing Muscles Normal-Appearing Muscles 0.3 0.6 0.0 Worsening p=0.18 Change from BL (p.p.) Change from BL (p.p.) C
Slide 11: Losmapimod Showed Significant Improvement Reachable Workspace
Losmapimod Showed Significant Improvement Reachable Workspace* ▪ Placebo group lost about 2% to No Weight at 48 weeks 4% of Total Surface Area (with and Total Surface Area without weight) • Placebo (n=29) Non-Dominant • Losmapimod (n=26) ▪ Losmapimod group showed trends of slower disease progression
Slide 12: Losmapimod Showed Improved Muscle Strength vs Placebo
Losmapimod Showed Improved Muscle Strength vs Placebo* ▪ Placebo group lost about 15% of • Placebo Dynamometry (Max) • Losmapimod shoulder and ankle dorsiflexors strength after 48 weeks PBO LOS Right Ankle (n=12) (n=15) ▪ Losmapimod group Dorsiflexors p=0.05 Left Ankle ▪ Showed trends of slower prog
Slide 13: Trend in Decreasing Timed Up and Go Completion Time vs Placebo
Losmapimod-Treated Participants Showed a Trend in Decreasing Timed Up and Go (TUG) Completion Time vs Placebo* Average Completion Time p=0.30 1.25 Change from baseline at week 48 (sec) 1.00 0.75 > 0.5 second change from Placebo (p=NS) 0.50 Worsening 0.25 0.00 Placebo Losmapimod (n=29) (n=25) FULCRUM
Slide 14: Significant Improvement vs Placebo in Patient Global Impression of Change
Trial Participants Who Received Losmapimod Reported Significant Improvement vs Placebo* P ’ Gl b l Im f Ch PGIC (PGIC) evaluates the impression of change in study participants by asking 7 “Since the start of the study, my overall ✱ LS means at week 48 status is”: 6 p=0.02 5 Improvement Worsening (±S
Slide 15: Losmapimod-treated Patients Reported Feeling Better
Losmapimod-treated Patients Reported Feeling Better Four times as many losmapimod- 20% fewer losmapimod-treated treated patients felt better vs placebo patients felt worse vs placebo 30 3: Minimally improved 40 7: Very much worse 2: Much improved 35 6: Much worse 25 1: Very much improved 5: Minimall
Slide 16: FSHD-TUG, MFM, and FSHD-HI Did Not Demonstrate Differences
FSHD-TUG, Motor Function Measurement, and FSHD-HI Did Not Demonstrate Differences Between Losmapimod and Placebo* The placebo results suggest that these measures did not detect progression FSHD-TUG Motor Function Measure FSHD Health Index (FSHD-HI) Average Completion Time MFM Domain 1 Score Total FS
Slide 17: Losmapimod Was Generally Well Tolerated
Losmapimod Was Generally Well Tolerated With No Severe, Drug-Related Adverse Events ▪ Treatment-emergent adverse events (TEAEs) occurred in 29 (72.5%) losmapimod and 23 (57.5%) placebo participants ▪ For both losmapimod and placebo: ▪ The majority of TEAEs were assessed by the principal investigator
Slide 18: Totality of Evidence Supports Losmapimod as Potential Disease-Modifying Treatment for FSHD
The Totality of Evidence Supports Losmapimod as a Potential, Transformative Disease-Modifying Treatment for FSHD SAFETY AND TOLERABILITY DATASET PHARMACOKINETICS AND MOLECULAR >3600 subjects treated PHARMACODYNAMICS In vitro and in vivo data Extensive evaluations in patients Losmapimod for FSHD FUNC
Slide 19: REACH Trial Design Leverages Learnings from ReDUX4
REACH Trial Design Leverages Learnings from ReDUX4 What we know from ReDUX4 REACH Phase 3 Trial Design Losmapimod demonstrated measurable impact on disease progression at 48 weeks 48-week treatment duration of treatment Reachable Workspace (RWS) is a reliable and quantifiable measure of function and
Slide 20: REACH: A Phase 3 Trial of Losmapimod in FSHD
REACH: A Phase 3 Trial of Losmapimod in FSHD Aligned with regulators on key aspects of trial design; plan to initiate REACH in Q2 2022 Study Population Subjects with FSHD Aged 18 – 65 Baseline Assessment 7-Day Safety & Randomization Follow-Up 48-Week Placebo-Controlled Treatment Period 28-day Placeb
Slide 21: Acknowledgements
Acknowledgements People Living With FSHD Participating in This Study Collaborating Organizations ReDUX4 Study Sites Principal Investigator Rabi Tawil, MD. URMC ReDUX4 Physical Therapists Site Investigators ▪ Alan Pestronk, MD. WUSTL ReDUX4 Study Coordinators ▪ Angela Genge, MD. Montreal Neurological
Slide 22: Thank you!
Fulcrum Therapeutics, Inc. 26 Landsdowne Street Cambridge, MA, USA 02139 [email protected] Thank you! 22